NCT07122674 18F-Pentixafor PET in Hematologic Malignancies
| NCT ID | NCT07122674 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Condition | Hematological Malignancies |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-07-01 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.
Eligibility Criteria
Inclusion Criteria: 1. Age of 18-80 years old, both sexes, with behavioral capacity; 2. patients with suspected or confirmed hematological malignancies; 3. 18F-FDG PET or other imaging examinations should be performed according to the treatment plan; 4. For suspected patients, biopsy or needle biopsy is expected to obtain pathological results; 5. Can provide informed consent, can understand and comply with the requirements of the study. Exclusion Criteria: 1. pregnant and lactating women; 2. patients with fear or radiophobia, or with mental disorder or primary affective disorder; 3. received ionizing radiation outside the scope of this study for clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv; 4. received investigational drugs or devices of uncertain efficacy or safety within 1 month; 5. Any condition that the chairpersons of the study consider that any link related to the study may cause harm or have potential harm.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07122674 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hematological Malignancies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07122674 currently recruiting?
Yes, NCT07122674 is actively recruiting participants. Contact the research team at wpp199411@163.com for enrollment information.
Where is the NCT07122674 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07122674 clinical trial?
NCT07122674 is sponsored by First Affiliated Hospital of Zhejiang University. The trial plans to enroll 100 participants.